Company / R&D per Share
Protagonist Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.51
FY2025
5-year range
$2.12 / $2.72
FY2021-FY2025
Trend
+18.1%
vs FY2024
Sector context
#85 of 208
Health Care
What the data says
At $2.51, Protagonist Therapeutics, Inc.'s r&d per share ranks #85 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $2.12 in FY2023 to $3.95 in FY2016.
Based on SEC 10-K filings.
2.51 in FY2025 with a 5-year CAGR of +3.0%.
Improved from $2.12 to $2.51 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -0.9%
- 5-Year CAGR
- +3.0%
- 10-Year CAGR
- -
Sector benchmark
#85 of 208 in Health CareTop 41% of 208This company $2.51 Sector average $28.82
▼
-91.3% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 18.1% year-over-year.
- Ranks #85 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2016.
- Lowest r&d per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.51 | +18.1% |
| FY2024 | $2.12 | +0.3% |
| FY2023 | $2.12 | -17.7% |
| FY2022 | $2.57 | -5.4% |
| FY2021 | $2.72 | +25.6% |
| FY2020 | $2.17 | -13.7% |
| FY2019 | $2.51 | -5.6% |
| FY2018 | $2.66 | +1.9% |
| FY2017 | $2.61 | -34.0% |
| FY2016 | $3.95 | -91.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026